Xponance Inc. Buys 3,480 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Xponance Inc. lifted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 22.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 19,163 shares of the company’s stock after acquiring an additional 3,480 shares during the period. Xponance Inc.’s holdings in Recursion Pharmaceuticals were worth $130,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RXRX. Farther Finance Advisors LLC lifted its stake in Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares during the last quarter. Wedmont Private Capital raised its holdings in shares of Recursion Pharmaceuticals by 10.6% during the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock valued at $144,000 after buying an additional 2,000 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in Recursion Pharmaceuticals by 28.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock worth $69,000 after buying an additional 2,235 shares during the last quarter. Green Alpha Advisors LLC boosted its stake in Recursion Pharmaceuticals by 3.6% in the fourth quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock worth $454,000 after buying an additional 2,346 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Recursion Pharmaceuticals by 5.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock valued at $346,000 after acquiring an additional 2,667 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

RXRX has been the subject of a number of research reports. Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, KeyCorp dropped their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Price Performance

RXRX stock opened at $5.81 on Friday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average price is $7.44 and its two-hundred day moving average price is $7.01. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of -3.80 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The business had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s revenue for the quarter was down 57.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.42) EPS. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.